NovaBay Pharmaceuticals with ticker code (NBY) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 3.5 and 2.2 with the average target price sitting at 2.85. Now with the previous closing price of 0.55 this is indicating there is a potential upside of 418.2%. There is a 50 day moving average of 0.6 while the 200 day moving average is 0.67. The company has a market cap of $25m. Visit the company website at: http://www.novabay.com
NovaBay Pharmaceuticals, a medical device company, develops products for the eye care markets in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market. It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and CelleRx Clinical Reset through online sales channels. The company was formerly known as NovaCal Pharmaceuticals and changed its name to NovaBay Pharmaceuticals in February 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is headquartered in Emeryville, California.